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1. Introduction
Cutaneous malignant melanoma is the most agressive skin cancer with rising incidence in the
last years [1]. Nowadays, the only treatment to cure melanoma is the early diagnosis and
surgical removal of the primer tumor. New research directions developed in order to discover
markers for early detection and therapeutic response of melanoma, treatments that could
improve the survival rate. Recent studies showed that melanoma is a heterogeneous group of
complex molecular disorders [2-16]. The diversity of these alterations sustain the importance
of, on one hand, an individualized diagnosis, prognosis and treatment of melanoma patients,
and, on the other hand, the detection of new biomarkers and therapeutic approaches in these
patients.
The development of new research and investigation techniques in the last years, offered
information regarding pathogenesis of melanoma. The skin is considered a hypoxic organ and
the low level of oxygen induces the transcription of some hypoxic markers. The cells respond
to hypoxia by stimulating the synthesis of some heterodimeric factors, composed by alpha
inductible subunit (hypoxia inducible factor alpha-HIF alpha) and beta subunit (aryl hydro‐
carbon receptor nuclear transducer ARNT). Cutaneous melanocytes, from the dermic-
epidermic junction, lay in a low oxygen medium [16, 17]. Tissue hypoxia can modify cellular
behavior by direct influence on: cell cycle, cellular metabolism, differentiation, proliferation
and survival, degradation and remodeling of extracellular matrix, tumor migration, invasion
and metastasis, angiogenesis, apoptosis, cells sensitivity to antitumor therapy (Table 1) [16-29].
Cells ability to adapt to hypoxia is mediated by several transcription factors. A major role in
cells response to hypoxia is played by HIF 1 alpha. Its expression and tissue distribution are
influnenced by many factors [3, 30-38]: modulators of cellular degradation (EPF, UCP, VDU2,
Sumoylation, DeSUMOylation, Prolyl hydroxylases, PVLH, OS-9, SSAT 1, SSAT 2, GSK3 beta,
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FOXO 4, Calcineurin A), modulators of translation (RNA-binding protein, PTB and HuR,
PtdIns3k and MAPK pathways, IRES-mediated translation, calcium signaling bng, miRNA).
Function Gene
Cell metabolism Iron - Erythropoietin (EPO); Transferrin; Transferrin receptor (TfR); Ceruloplasmin
pH - Carbonic anhydrase-9, 12
Nucleotide - Adenylate kinase; Ecto-5-nucleotidase
Aminoacids - Transglutaminase 2;
Glucose - Adenylate kinase; Aldolase A,C (ALDA,C); Carbonic anhydrase-9,-12; Enolase- 1
(ENO1); Glucose transporter-,1,3 (GLU1,3); Glyceraldehyde phosphate dehydrogenase
(GAPDH); Hexokinase1,2 (HK1,2); Lactate dehydrogenase-A (LDHA); Pyruvate kinase M
(PKM); Phosphofructokinase L (PFKL); Phosphoglycerate kinase 1(PGK1); 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphonate-3 (PFKFB3).
Lipids-Sphingosine kinase 1 (Sphk 1); Lpin 1.
Matrix metabolism Matrix metalloproteinases (MMPs) ; Plasminogen activator receptors and inhibitors (PAIs);
Collagen prolyl hidroxylase .
Cytoskeletal structure Keratin 14,18,19 (KRT 14,18,19); Vimentin
Mitochondrial respiration Pyruvate dehydrogenase kinase1 (PDK1) ; Monocarboxylate transporter (MCT4) ;
Cytochrome c oxidase (COX1-4).
Transcriptional regulation Differentiated embryo-chondrocyte exppressed gene 1,2 (DEC1,20; Nuclear receptor 77
(NUR77); v-ets erythroblastosis virus E26 oncogene homolog1 (ETS1).
Vascular tone Nitric oxide synthase2 (NOS2); Heme oxigenase ; Endothelin 1 (ET1) ; Adrenomedullin
(ADM); Alpha-,beta-adrenergic receptor
Stem cells KLF4; Nanog; Oct-3/4; Oct-4A,SOX2; Wnt/beta-catenin.
Cell proliferation/ survival Insulin-like growth factor-2 (IGF2) ; IGF-factor binding protein 1,2,3 (IGF-BP1,2,3);
Adrenomedulin (ADM); Coiled-coil-DIX1 (CCD1); Transforming growth factor alpha,beta
(TGF alpha,beta); Cyclin G2; Survivin ; Notch-1; Nitric oxide synthase 2 (NOS2); P21;
Erythropoietin.
Cell differentiation Notch signal activation; Tertiary complex p300/HIF1/STAT3/ROR gamma; Multistructural
complex Foxp3/pVHLE3/HIF1/nUb
Cell migration/invasion Collagen V; Autocrine motility factor/ glucose-6-phosphate isomerase (AMF/GPI);
Cathepsin D(CATHD); Integrin-linked kinase; Integrins; Lysyloxidase (LOX); Plasminogen
activator receptor and inhibitor1 (PAI1); LDL receptor-related protein1 (LRP1); Microneme
protein2/ CD99 (MIC2/CD99); Fibronectin; Urokinase plasminogen activator receptor
(UPAR); Proto-oncogenes c-MET; Chemokine receptor type4 ( CXCR4) ; MMP2
Angiogenesis Proangiogenic - Vascular endothelial growth factor/receptors (VEGF, Flt-1 /VEGfF-R1,
Kdr/VEGF-R2); Endocrine-gland-derived VEGF (EG-VEGF); Leptin (LEP); Transforming
growth factor –beta 3 (TGF-beta3); Angiopoietin 1,2 (Ang-1,2); TEK- tyrosine kinase
endothelial (Tie-2); Adrenomedullin (ADM) ; Fibroblast growth factor (FGFs) ; Placenta
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Function Gene
growth factor (PLGF); Plateled-derived growth factor- beta (PDGF); Stem cell factor (SCF);
Osteopontin; Plasminogen activator receptor and inhibitor -1 (PAI-1); Matrix
metalloproteinases (MMPs); Tissue inhibitor of metalloproteinases (TIMPs); Nitric oxide
synthase (NOS2); Cyclo-oxigenase-2 (COX-2); Endoglin; Alpha, beta-Adrenergic receptor;
Endothelin-1; Semaphorin-4D; Integrins; Leptin; Endosialin; Adenosine A2A receptor ;
Oxygen regulated protein-150; Stromal derived growth factor-1 (SDF-1); Interleukins (IL 1,
2, 4, 6, 8, 10).
Antiangiogenic - Delta-like ligand 1-4 (DLL1-4); Carbonic anhydrase-9; Vasohibin-1;
Thrombospondin-1; Regulator of G-protein signaling 5; Angiostatin; Endostatin; Canstatin;
Interferons (alpha, beta, gamma).
Neovessel formation - FGFs/FGFRs; PDGF-B/PDGFR; PLGF/VEGFR1(Flt-1);
Thrombospondin-1/CD36,CD47,integrins; Integrins/Extracellular matrix; SDF-1/CXCR4L
SCF/c-kit; DLL1-4/Notch; Interleukins/Interleukin receptors; Wnt/beta-catenin.
Cell maturation - Vasohibin-1/vasohibin receptors; Endothelin receptors(Et-A,Et-B);
Angiopoietin1/Tie-2; PDGF-B/PDGFR
Cell apoptosis Bcl2/adenovirus EIB19KD-interacting protein3 (BNip3); Nip3-like protein X(NIX);
Regulated in development and DNA damage responses1 (RTP801/REDD1); Redox factor-1
(Ref-1); Nuclear factor kappa B (NFKB); Heat shock protein 70 (HSP70); P53; Bax; Puma/
Bax; Bcl-2-Interacting Domain (BID).
Metastasis Twist upregulation; CXC chemokine CCL2/ JE/MCP-1; HGF-R/c-MET; CTGF/CCN2; ZEB1;
TCF-3/E2A; Snail; MKP-1; MMPs upregulation; E-cadherin downregulation.
Drug metabolism Multidrug resistance gene/P-glycoprotein (MDR!/P-GP); Multidrug resistance – associated
protein1 (MRP!).
Table 1. Representative target genes of Hypoxia-Inducible Factor1 (HIF1) and their functions [17-29].
Post-translational changes (polyubiquitination by PVHL-signaling for degradation, lysine
acetylation by ARD1-facilitating PVHL binding) influence HIF activity. Biological disponibil‐
ity of HIF 1 alpha might be altered by enviromental regulators (nickel, cobalt, arsenite,
chromium, cadmium, desferroxamine, cigarette smoking, UVB, cytokines, hormones, onco‐
genes). Alterations in HIF-signaling pathways have major role in initiation and progression of
malignant tumors (Table 1) [17-38]. Recent studies confirmed that HIF 1 alpha controls the
expression of some genes involved in melanoma biology [39, 40]. Changes in lipids biochem‐
istry associated with HIF overexpression were described in different types of neoplastic cells.
Hypoxia promotes synthesis of free fatty acids, cholesterol, phospholipids, hormones,
prostaglandins, leucotriens, sphingolipids. Cellular lipid uptake is increased in hypoxic
conditions due to the interactions between lipids and hypoxia signaling pathways [41, 42].
These imbalances induce alteration of cell cycle, cellular proliferation, apoptosis, signal
transduction, or alteration of antigenic structure of cellular membranes. Some studies reported
the expression of an extensive adipose gene in pVHL cancer, in which HIF is constitutively
activated [43]. Hypoxia inducible genes influence lipid droplet formation (hypoxia-inducible
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protein 2), prostaglandin biosynthesis (cyclooxygenase 2), lipid signaling systems (lipoxyge‐
nase 12-lox, sphingosine kinase, SphK1) and synthetic processes (stearoyl-CoA desaturase-1,
a rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids) [44-47]. Some of
these genes are direct targets of HIF, while others are up-regulated by transcriptional factors
HIF-dependent. Hypoxia interacts with transcriptional networks involved in lipid metabo‐
lism, including sterol response element binding proteins (SREBPs), DEC1/2 and GATA2/3
[9-11, 48-52].
Gangliosides form lipoproteic domains in cells membrane and affect series of fundamental
biological processes like cell signal transduction, cell growth and differentiation, imune
responses, cell transformation and degradation. Reference researches about gangliosides
system in malignant tumors offer new data, useful for a better understanding of melanoma
biology. Melanoma development needs high levels of oxygen and substances over the offer of
the existent blood vessels. Angiogenesis is promoted under these conditions [10, 51]. The main
stimuli of the angiogenic switch are: HIF 1alfa, low ph, hypoglycemia, presence of reactive
oxygen/nitrogen species, inflammation. In hypoxic conditions, melanoma cells release
proangiogenesis (VEGFs, FGFs, PDGF, HGF, TGF, TNF, PGF, Ang-1, IL8) and antiagiogenesis
(trombospondin, angiostatin, endostatin, Ang2, IFNs, IL12, fibronectin, TIMPs, PAI-1,
dopamine, retinoic acid, vitamin D) factors [56-58]. These molecules interact with RTKs
signaling pathway from melanoma cells, endothelial cells, pericytes, immune cells. Ganglio‐
sides and their degradation products could influence angiogenesis in malignant melanoma by
multiple mechanisms [59-61]. Monosialogangliosides and gangliosides in b series counteract
the effects of proangiogenic growth factors, while complex gangliosides control endothelial
cell response to the action of proangiogenic factors. Lisogangliosides and sphingosine inhibit
the activity of protein-kinase associated growth factors, GM1 and GM3 inactivate PDGFR,
GD1a and GD1b inactivate PKC, GM3 inhibits EGFR, GD1a and GQ1b intensify the activity
of calcium/calmoduline dependent kinase [54, 61].
Gangliosides control cell differentiation and proliferation [62-64]. Monosialogangliosides
suppress cell growth (GM1-MMP9, GM1-PDGF, GM1-NGF, GM3-EGF, GM3-IGFs, GM2-
pFAK), while polisialogangliosides stimulate cell growth (GD3 binding integrin, p-FAK,
pp130Cas, p=paxilin, p-Yes or GD2 binding p-FAK, p-p38, c-Met) [65]. The transduction
mechanism is complex including complex signaling pathways (p38-MAPK, Erk1/2, p13k/AKT,
JNK1/2/3) [65-70]. Gangliosides act as inhibitors or promoters of cell apoptosis in melanoma
[71, 72]. GD3 induces apoptosis by activating caspases and stimulates production of reactive
oxygen species (ROS). GD3 acetylation cancels apoptotic effect of GD3, conferring resistance
to antitumor therapy [73, 74]. GM3 induces apoptosis by intracellular accumulation of
ceramide; GM1 stimulates apoptosis by disrupting the flow of intramitochondrial calcium
[73-75].
GD1b, GT1b, GQ1b have inhibitor effects on adenylate cyclase in peripheral T cells and
suppress the production of cytokines, controlling humoral immune response (IL4, IL5) [76].
GM1 and GD1a inhibit the activity of protein-kinases involved in the immune response. GQ1b
promotes production of immunoglobulins [74, 77, 78]. Anti-GD2 antibodies modify integrin
conformation through signaling pathways FAK, ERK, p38/MAPK [74, 77, 78].
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Gangliosides influence anticancerous therapy through several mechanisms [51, 79-85] i)
overexpression of proangiogenic factors; ii) functional mutations in tumor suppression genes;
iii) overexpression of some oncogenes conferring resistance to hypoxia, and though instability
of genes and inhibition of apoptosis; iv) impaired detoxification and DNA repair mechanisms;
v) mutations of endothelial cells; vi) selective activation of genes associated with melanoma
resistance to apoptosis; vii) cells inability to accumulate sphingosine, sphingaanine and
ceramide; viii) ability of melanoma cells to acetylate gangliosides.
In a recent study the authors showed that malignant fenotype was associated with overex‐
pression of ganglioside sialic acid on the membranes of melanoma cells. The tissue level of
ganglioside sialic acid was correlated with histological markers of melanoma (Breslow index,
Clark level, presence/absence of ulceration) [53]. The gangliosides identified in melanoma
were complex (Fig. 1) and they could be used as a differentiation marker between normal and
malignant tissue [55]. The model of membranous gangliosides was characteristic for a cell type
and for a tumor stage. The observed gangliosides in malignant melanoma were:
GD3>GM3>GD2>GM2>O-Ac GD3>GD1a>GT1b>GD1b>GQ1b>GM1; in dysplastic nevi:
GD3>GM3>GD2>GM2>GM1; in healthy tissue around the tumor:
GM3>GM2>GD3>GD2>GM1. The transition from radial to vertical growth of melanoma was
followed by high synthesis of polisialogangliosides [53].
The compositional analysis of gangliosides in melanocytic tumors showed that aberant
glycosilation of sphingolipids could stimulate or inhibate invasion and metastasis of malignant
tumor cells. High levels of monosialogangliosides could be found in benign tumors with slight
evolution and in healthy tissue. Polisialogangliosides had high levels in malignant prolifera‐
tions with quick and irregular evolution. A special attention was given to gangliosides
acetylation in malignant melanoma. Acetylated gliocsphigolipids were determined only in
melanoma cells with vertical development. O-acetylation was selectively on disialoganglio‐
sides and was associated with metastasis of malignant melanoma [53].
Another research subject was the immunogenic potential of melanoma-associated ganglio‐
sides. Several tumor gangliosides induced the synthesis of antiganglioside antibodies in
melanoma patients [9, 85-92]. The role of these antibodies is a subject of great current interest
in medical research [9, 10, 78, 90, 93]. The data regarding endogenous immune response against
gangliosides in melanoma patients and its pathophysiological relevance in management of
melanoma were the main interests of the authors.
The objective of the study was to evaluate the role of gangliosides and antiganglioside
antibodies in detection, staging and progression of cutaneous malignant melanoma. We aimed
to determine the status of serum gangliosides and antiganglioside antibodies in patients with
untreated malignant melanoma compared with patients with dysplastic nevi and control, their
variation with surgical removal of the tumor and the relation between these parameters and
some histological/biochemical factors used for melanoma staging (accepted by American Joint
Committee of Cancer).
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2. Materials and method
The study lasted five years and was based on the prospective-observational analysis of patients
with melanocytic lesions. All the patients in the study signed the informed consent accordind
with the Declaration from Helsinki in 1964. Our study included three groups: malignant
melanoma group (128 adult patients diagnosed with malignant melanoma, with adequate
nutritional status, without associated diseases, with no treatment for melanoma before the
inclusion in the study), dysplastic nevi group (48 adult patients with dysplastic nevi without
associated diseases) and control group (48 healthy subjects). The groups were similar for age,
sex and nutritional characteristics.
Figure 1. Metabolism of gangliosides in malignant melanoma. GM1=Gal-3GalNAc-4(Neu5Ac-3)Gal-4GlcCer; GM2=Gal‐
NAc-4(Neu5Ac-3)Gal-4GlcCer; GM3=Neu5Ac-3Gal-4GlcCer; GD1a=Neu5Ac-3Gal-3GalNAc-4(Neu5Ac-3)Gal-4GlcCer;
GD1b=Gal-3GalNAc-4(Neu5Ac-8Neu5Ac-3)Gal-4GlcCer;  GD2=GalNAc-4(Neu5Ac-8Neu5Ac-3)Gal-4GlcCer;
GD3=Neu5Ac-8Neu5Ac-3Gal-4GlcCer;  GT1b=Neu5Ac-3Gal-3GalNAc-4(Neu5Ac-8Neu5Ac-3)Gal-4GlcCer;
GQ1b=Neu5Ac-8Neu5Ac-3Gal-3GalNAc-4(Neu5Ac-8Neu5Ac-3)Gal-4GlcCer;  O-acetyl-GD3=Acetyl-O-
Neu5Ac-8Neu5Ac-3Gal-4Glc1Cer;  Glc=glucose;  Gal=galactose;  GalNAc=N-acetyl-galactosamine; NeuAc=neuraminic-
acid; Cer=ceramide; NANA=N-acetyl-neuraminic-acid.
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No patients with age under 18 years, pregnancy, alcoholism or drug dependence, with any
hormonal, antidepressive, antioxidant, with MAO inhibitors or blockers of dopaminergic
receptors treatment or with associated diseases (neurological, psychiatric, digestive, endo‐
crine, cardiovascular, hepatic, renal, pulmonary, metabolic, autoimmune disorders, chronic
infections/inflammation, others neoplastic diseases) were included in the study.
The diagnosis protocol was based on clinical examination, common haematological and bio‐
chemical determinations for all the patients in the study. The histological and immunohisto‐
chemical analysis were made for the patients with malignant melanoma and dysplastic nevi.
After the diagnosis, in malignant melanoma and nevi groups the tumors were surgically
removed. In all the patients included in the study we determined molecular markers that could
indicate melanoma progression (lactate dehydrogenase, interleukin 8, C reactive protein);
gangliosides and antigangliosides.
In nevi and melanoma groups, the variations of these factors were evaluated in six moments:
T0-when included in the study; T1 – 8 weeks after surgical removal of the tumour, at 3(T2), 6
(T3), 12 (T4), 18 (T5) and 36 (T6) months after surgical removal of the tumour. In melanoma
group, the variations of gangliosides and antigangliosides were analysed in relation to serum
factors – lactate dehydrogenase, interleukin 8, C reactive proteins and histological factors –
Breslow index, Clark level, presence/absence of ulceration.
2.1. Clinical and biological characteristics of melanoma patients
The clinical examination showed the following localization of cutaneous malignant melanoma:
64% on trunk, 21% on limbs, less than 10% on head and neck (Fig. 2). By histological charac‐
teristics, we found nodular melanoma in 60 patients (47%), superficial melanoma in 22 patients
(17%), acral lenticular melanoma in 9 patients (7%) and unclassified melanoma in 22 patients
(17%) (Fig. 3).
Figure 2. Anatomical site of melanomas
From patients with melanoma, 28 cases (22%) had Clark II, 47 cases (37%) had Clark III, 36
cases (28%) had Clark IV, 17 cases (13%) had Clark V. None of the patients included in the
study had Clark I melanoma. From the patients with melanoma, 20.68% had Breslow under
1.00mm, 24.82% Breslow 1.01-2.0mm, 19.71% Breslow 2.01-3.0mm, 18.49% Breslow over
3.01mm. The ulceration was present in 12.5% patients with melanoma. After staging melano‐
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ma, we identified melanoma stage I – 51 cases, stage II – 54 cases, stage III – 54 cases, stage IV
– 9 cases (Fig. 5).
The  researchers  in  melanoma  field  considered  lactatdehydeogenase  (LDH),  C  reactive
protein (CRP),  interleukin 8  (IL8)  useful  for  melanoma follow-up.  High serum levels  of
those  markers  indicate  the  progression  of  melanoma.  We  presented  their  levels  in  the
studied groups in Table 2.
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Figure 3. Histological features of melanomas
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Figure 5. Clinical stages of melanomas
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Groups LDH (U/L) CRP (mg/dl) IL8 (pg/ml)
Melanoma 389±217 1.07±0.88 68.9±17.2
Dysplastic nevi 241±88 0.26±0.23 28.7±13.3
Control 207±82 0.12±0.12 10.9±4.6
Table 2. Serum level of LDH, CRP and IL8 in melanoma, dysplastic nevi and control groups
In melanoma group, LDH had the following levels at T0: in 0.5% cases smaller than 120U/L,
in 73% between 120 and 450 U/L and in 26.5% over 450U/L. In dysplastic nevi patients and in
control group, LDH level varied between 120 and 450 U/L. We considered the interval
120-450U/L as normal values for LDH. CRP was in 19% patients between 0 and 0.30mg/dl, in
47%patients between 0.30-0.60mg/dl and in 33% over 0.60mg/dl. We considered the interval
0.30-0.60mg/dl as normal level for CRP. IL8 is a marker of angiogenesis. We considered the
normal level for IL8 5-42pg/ml. In melanoma group, IL8 had the following levels: in 16%
patients under 15pg/ml, in 22% patients between 15 and 42pg/ml, and in 62% over 42pg/ml.
2.2. Statistical analysis
All the results were analysed using SPSS, a soft for statistic determinations. The results were
presented as mean±standard deviation. The variations between groups were determined using
t test or ANOVA test. The correlations between groups were calculated using linear regression
and Pearson coefficient. p<0.05 was considered with statistical significance. We evaluated the
relapse-free survival using Kaplan-Meier curves.
2.3. Laboratory methods
Serum determination of gangliosides. The assessment of gangliosidic acid (LASA) had the
following steps: 50 microliters serum were diluted with 150 microliters of cold distilled water
and the solution was shacked. There were added 3 ml of choloroform:methanol (v/v) 2:1, at
4-5 celsius degrees. The extraction and partition was finished after adding 0.5ml of cold
distilled water. After separating the phases by centrifugation, sialic acid was titred with
resorcinol-chlorhidric acid [94].
Sialic  acid  assessment  by  resorcinol  method.  Sialic  acid,  after  the  cleavage  from glicoconju‐
gates through acid hydrolysis, reacted with resorcinol in acid solution, in the presence of
divalent cooper ions. Thus, it  formed a blue-violet complex. The complex was evaluated
by photometric determination at 580nm, after extraction in a mixture of butanol-acetate and
butyl-acetate [95, 96].
Serum assessment of antiganglioside antibodies. Antiganglioside antibodies were assessed using
Euroline kits, by Immunoblot, a technique for in vivo determination (serum or plasma) of
human antiganglioside antibodies Ig G and IgM type. We evaluated the immune response
against seven types of ganglioside: GM1, GM2, GM3, GD1a, GD1b, GT1b and GQ1b. The test
kit contained strips coated with parallel lines of purified antigens [97].
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3. Results
3.1. Serum profile of gangliosides
Serum gangliosides had increased levels in melanoma and nevi patients compared with
control, before the surgical removal of the tumours. In metastatic melanoma, gangliosides
levels were statistically significant higher than in melanoma without metastasis (Table 3).
Serum gangliosides had a statistically significant decrease after the surgical removal of the
tumour in patients with primary melanoma (39.82± 21.13 vs 57.29±17.61mg/dl, p<0.05). In
patients with metastatic melanoma, respectively, dysplastic nevi, no statistically significant
variations were determined with surgical removal of the tumour.
Groups Gangliosides (mg/dL) p1 p2
Control 18.02±2.78 - 1
Dysplastic nevi 18.86±3.27 1 0.88
Malignant melanoma 57.29±17.61 0.04 0.03
Metastatic melanoma 80.14±19.26 0.00 0.00
p1-melanoma, metastasis vs dysplastic nevi, p2-melanoma, metastasis, dysplastic nevi vs control group
Table 3. Serum levels of gangliosides in melanoma, dysplastic nevi and control groups
Serum gangliosides were analyzed in relation to age, sex, histological characteristics of
melanoma (Breslow index, Clark level, histological type of the tumor, presence/absence of
ulceration) (Table 4). Serum gangliosides did not vary significantly with age and sex, with
tumor localization. Serum gangliosides had statistically significant increased values in patients
with high Breslow index, respectively high Clark level. We analyzed serum level of ganglio‐
sides for the same Clark level in relation to Breslow index and histological type of melanoma
(Fig 6).
Parameters Serum gangliosides (mg/dl) P
Women 19.06±2.66
p1=0.18Men 18.17±2.85
Tumor localization
Head-neck 49.20±6.23
p2=0.30Trunk 77.31±19.42
Limbs 66.81±12.51
Histological type
Nodular melanoma 81.61±27.43
p3=0.03Extensive in surface melanoma 36.42±18.55
Lenticular malignant melanoma 72.53±27.51
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Parameters Serum gangliosides (mg/dl) P
Acral lenticular malignant melanoma 44.17±16.51
Breslow index
0-1.0 mm 32.67±9,23
p4=0.02
1.01-2.0 mm 50.88±9.74
2.01 – 3.0mm 73.12±23.19
3.01-4.0mm 89.15±2.31
Clark level
II 25.92±8.93
p5=0.01
III 33.42±16.75
IV 62.37±20.91
V 78.01±20.66
Ulceration
Melanoma with ulceration 55.87±13.11
p6=0.04Melanoma without ulceration 39.72±12.33
p<0,05 was considered with statistically significance for IC=95%. p1-women vs men, p2-trunk vs limbs, p3-nodular melanoma vs
extensive in surface melanoma, p4-Breslow<1.0mm vs Breslow>3.01mm, p5-Clark II vs Clark V, p6-ulcerated melanoma vs mela‐
noma without ulceration
Table 4. Serum gangliosides in relation to clinical and histological features of melanoma
Figure 6. Graphical representation of serum levels of gangliosides in melanoma for the same Clark level in relation to
Breslow index (p<0.05) and histological type of tumour (p>0.05) NM-nodular melanoma, MLM-lenticular melanoma,
ALM-acral lenticular melanoma, SSM-extensive in surface melanoma
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The correlation coefficient showed a positive relation between ganglioside levels and Clark
level (r=0.60, CI=0.30-0.90, p<0.05), respectively, Breslow index (r=0.31, CI=0.19-0.58, p<0.05).
For the same Clark level and Breslow index, the production of gangliosides was higher in
nodular melanoma and in lentigous acral malignant melanoma compared with lenticular acral
melanoma and extensive in surface melanoma (Figure 6).
3.2. Serum profile of antiganglioside antibodies
The immune response against gangliosides GM1, GM2, GM3, GD1a, GD1b, GT1b, GQ1b was
evaluated by antiganglioside antibodies IgG and IgM type, before the surgical removal of the
tumor. The types of antiganglioside antibodies in melanoma, dysplastic nevi and control group
will be presented in this section only for moment 0. We considered antiganglioside antibodies
negative when signal intensity was undetectable (0-5) or low (5-10) and positive when signal
intensity was medium (11-50) or high (>50).
3.2.1. Anti-GM1 prevalence in studied groups
In patients with malignant melanoma, antiganglioside antibodies anti-GM1 IgG type were
undetectable in 90.62% patients, with low intensity of the signal in 4.69% patients, with
medium intensity of the signal in 4.68% patients. In dysplastic nevi group, 91.64% patients had
undetectable IgG antibodies, in 8.33% the signal was low. In the control group we did not
detect any positive anti-GM1 of IgG type. 72.65% patients with melanoma had signal of anti-
GM1 IgM class negative, 11.71% low signal,13.29% medium signal and 2.34% high signal.
88.33% patients with dysplastic nevi had negative IgM anti-GM1 signal, in 10.42% the signal
intensity was low, in 6.25% medium. In 93.75% healthy patients IgM antibodies had negative
signal, in 4.17% the signal was low, in 2.08% medium. In melanoma patients anti-GM1 IgG
type were positive in 4.68% cases and IgM in 15.63% cases. No statistical differences were
observed in anti-GM1 IgG class status between melanoma, dysplastic nevi and control group.
Anti-GM1 IgM class varied significantly between the studied groups (Table 5).
Groups Antibodies type Positive Negative P
Melanoma
IgG 6 122 NS
IgM 20 108 0.00
Dysplastic nevi
IgG 0 48 NS
IgM 3 45 NS
Control
IgG 0 48 1
IgM 1 47 1
p-melanoma vs control, dysplastic vs control, NS=no statistical significance
Table 5. Anti-GM1 IgG and IgM class in patients with malignant melanoma, dysplastic nevi and control
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Due to its statistically significant variation, we analysed IgM status in relation to clinical and
histological features of melanoma. Anti-GM1 status was analyzed in relation to age, sex,
histological characteristics of the tumor (Breslow index, Clark level, histological type of the
tumor, presence/absence of ulceration) (Table 6).The intensity of the signal did not vary with
sex and age. Anti-GM1 varied with histological type: in patients with nodular melanoma the
intensity signal was significantly increased compared with acral lenticular melanoma (p<0.05),
extensive in surface melanoma (p<0.05) or lenticular melanoma (p<0.05).
Parameters IgM intensity signal P
Sex
Women 8.96±18.28 p1=0.14Men 5.14±11.09
Tumor site
Head-neck 13.28±9.86
p2=0.02Trunk 8.87±17.30
Limbs 0.88±1.24
Histological type
Nodular melanoma 13.26±19.28
p3=0.00
Extensive in surface melanoma 0.82±1.11
Lenticular melanoma 0.77±0.97
Acral lenticular melanoma 1.31±0.65
Breslow index
0-1.0 mm 0.82±1.11
p4=0.00
1.01-2.0 mm 2.53±1.15
2.01 – 3.0mm 9.18±6.82
>3.01 mm 13.65±15.59
Clark level
II 1.07±1.30
p5=0.00
III 1.07±0.97
IV 12.61±14.85
V 18.38±27.59
Ulceration
Melanoma with ulceration 36.43±23.86 p6=0.00Melanoma without ulceration 2.46±4.39
p<0.05 was considered with statistically significance for IC=95%. p1-women vs men, p2-trunk vs limbs, p3-nodular mel‐
anoma vs extensive in surface melanoma, p4-Breslow<1.0mm vs Breslow>3.01mm, p5-Clark II vs Clark V, p6-ulcerated
melanoma vs melanoma without ulceration
Table 6. Anti-GM1 antibodies IgM class in relation to clinical and histological features of melanoma
Gangliosides and Antigangliosides in Malignant Melanoma
http://dx.doi.org/10.5772/59176
373
Anti-GM1 IgM intensity signal was significantly increased in melanoma on head and neck,
compared with melanoma on trunk (p<0.05), respectively on limbs (p<0.05) (Table 6). Anti-
GM1 signal varied statistically significant with Breslow index and Clark level. Compared with
Breslow <1.0mm, signal intensity was significantly higher in patients with Breslow 2.01-3.0mm
(p<0.05), respectively Breslow>3.01mm (p<0.05). Compared with Clark II, signal intensity was
significantly higher in patients with Clark IV (p<0.05), respectively, Clark V (p<0.05). Signal
intensity of anti-GM1 IgM type antibodies was statistically significant increased in melanoma
with ulceration compared with melanoma without ulceration (p<0.05).
3.2.2. Anti-GM2 prevalence in studied groups
In patients with malignant melanoma, signal of antiganglioside antibodies anti-GM2 IgG type
was undetectable in 96.87% patients, with low intensity in 1.57% patients, with medium
intensity in 1.56% patients. In dysplastic nevi group, signal of antiganglioside antibodies anti-
GM2 IgG type was undetectable in 97.92% cases, with low signal in 2.08% cases. In patients
with malignant melanoma, signal of antiganglioside antibodies anti-GM2 IgM type was
undetectable in 58.59% patients, with low intensity in 21.10% patients, with medium intensity
in 4.68% patients and high intensity in 15.63% patients. In dysplastic nevi group, signal of
antiganglioside antibodies anti-GM2 IgM type was undetectable in 70.83% cases, with low
signal in 25.12% cases, and with medium intensity in 4.17% cases. In control group, anti-GM2
IgM type was undetectable in 91.67% volunteers, with weak signal in 6.25% and with medium
signal in 2.08% volunteers. Only anti-GM2 IgM class varied significantly between the studied
groups, therefore we analyzed IgM status by clinical and histological features of melanoma.
Groups Antibodies type Positive Negative P
Melanoma
IgG 2 126 NS
IgM 26 102 <0.05
Dysplastic nevi
IgG 0 48 NS
IgM 2 46 NS
Control
IgG 0 48 1
IgM 1 47 1
p-melanoma vs control, dysplastic vs control, NS=no statistical significance
Table 7. Anti-GM2 IgG and IgM class in patients with malignant melanoma, dysplastic nevi and control
Anti-GM2 IgM status was analyzed in relation to age, sex, histological characteristics of the
tumor (Breslow index, Clark level, histological type of the tumor, presence/absence of
ulceration) (Table 8). The intensity level did not vary with sex and age, with anatomical site of
tumor or histological type of melanoma, Breslow index, Clark level, respectively presence/
absence of ulceration.
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Parameters IgM signal intensity p
Sex
Women 19.24±28.46
p1=0.14Men 12.51±23.70
Tumor site
Head-neck 13.00±24.96
p2=0.35Trunk 15.12±25.39
Limbs 22.92±32.36
Histological type
Nodular melanoma 14.91±24.38
p3=0.51
Extensive in surface melanoma 12.47±20.84
Lenticular melanoma 14.51±26.60
Acral lenticular melanoma 23.77±37.34
Breslow index
0-1.0 mm 12.13±20.41
p4=0.30
1.01-2.0 mm 21.02±31.78
2.01 – 3.0mm 11.93±22.99
>3.01mm 18.80±28.25
Clark level
II 13.14±21.31
p5=0.63
III 18.48±30.80
IV 17.63±26.57
V 17.23±26.56
Ulceration
Melanoma with ulceration 13.43±21.73
p6=0.56Melanoma without ulceration 16.91±27.43
p<0.05 was considered with statistically significance for IC=95%. p1-women vs men, p2-trunk vs limbs, p3-nodular
melanoma vs extensive in surface melanoma, p4-Breslow<1.0mm vs Breslow>3.01mm, p5-Clark II vs Clark V, p6-ulcerated
melanoma vs melanoma without ulceration
Table 8. Anti-GM2 antibodies IgM class by clinical and histological features of melanoma
3.2.3. Anti-GM3 prevalence in studied groups
In patients with malignant melanoma, signal of antiganglioside antibodies anti-GM3 IgG type
was undetectable in 96.10% patients, with low intensity in 3.12% patients, with medium
intensity in 0.78% patients. In dysplastic nevi group, signal of antiganglioside antibodies anti-
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GM3 IgG type was undetectable in 87.50% cases, with low signal in 12.25% cases. IgG did not
vary significantly between groups. In patients with malignant melanoma, signal of antigan‐
glioside antibodies anti-GM3 IgM type was undetectable in 74.22% patients, with low intensity
in 8.59% patients, with medium intensity in 13.28% patients and high intensity in 3.91%
patients. In dysplastic nevi group, signal of antiganglioside antibodies anti-GM3 IgM type was
undetectable in 77.08% cases, with low signal in 18.75% cases, and with medium intensity in
4.17% cases. Anti-GM3 IgM class varied significantly between the studied groups (Table 9).
Groups Antibodies type Positive Negative P
Melanoma
IgG 1 127 NS
IgM 6 122 <0.05
Dysplastic nevi
IgG 0 48 NS
IgM 2 46 NS
Control
IgG 0 48 1
IgM 0 48 1
p-melanoma vs control, dysplastic vs control, NS=no statistical significance
Table 9. Anti-GM3 IgG and IgM class in patients with malignant melanoma, dysplastic nevi and control
Anti-GM3 IgM status was analyzed in relation to age, sex, histological characteristics of the
tumor (Table 10). The intensity level did not vary with sex and age, anatomical site or histo‐
logical type of tumor, Breslow index or Clark level. Anti-GM3 antibodies had statistically
significant higher intensity in ulcerated melanoma compared with melanoma without
ulceration (Table 10).
Parameters IgM signal intensity p
Sex
Women 10.42±19.74
p1=0.08Men 10.88.±19.57
Tumor site
Head-neck 11.85±15.87
p2=0.68Trunk 9.43±18.08
Limbs 15.01±25.07
Histological type
Nodular melanoma 7.73±12.84
p3=0.57Extensive in surface melanoma 14.81±24.57
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Lenticular melanoma 12.13±25.81
Acral lenticular melanoma 10.75±16.50
Breslow index
0,0-1.0 mm 15.72±25.48
p4=0.13
1.01-2.0 mm 11.94±22.79
2.01 – 3.0mm 12.37±15.93
>3.01mm 7.71±14.22
Clark level
II 13.11±23.58
p5=0.09
III 12.80±23.34
IV 9.13±13.89
V 4.66±8.56
Ulceration
Melanoma with ulceration 2.81±2.31
p6=0.00Melanoma without ulceration 11.82±20.66
p<0.05 was considered with statistically significance for IC=95%. p1-women vs men, p2-trunk vs limbs, p3-nodular mel‐
anoma vs extensive in surface melanoma, p4-Breslow<1.0mm vs Breslow>3.01mm, p5-Clark II vs Clark V, p6-ulcerated
melanoma vs melanoma without ulceration
Table 10. Anti-GM3 antibodies IgM class by clinical and histological features
3.2.4. Anti-GD1a prevalence in studied groups
In patients with malignant melanoma, signal of antiganglioside antibodies anti-GD1a IgG type
was undetectable in 89.06% patients, with low intensity in 10.16% patients, with medium
intensity in 0.78% patients. In dysplastic nevi group, signal of antiganglioside antibodies anti-
GD1a IgG type was undetectable in 95.83% cases, with low signal in 4.17% cases. No positive
anti-GD1a IgG type were detected in nevi or control groups. In patients with malignant
melanoma, signal of antiganglioside antibodies anti-GD1a IgM type was undetectable in
57.81% patients, with low intensity in 28.12% patients, with medium intensity in 3.12% patients
and high intensity in 10.94% patients. In dysplastic nevi group, signal of antiganglioside
antibodies anti-GD1a IgM type was undetectable in 77.08% cases, with low signal in 16.67%
cases, and with medium intensity in 6.25% cases. No positive anti-GD1a IgM type were
detected in nevi or control groups. No statistical differences were observed in anti-GD1a IgG
class status between melanoma, dysplastic nevi and control group. Anti-GD1a IgM class varied
significantly between the studied groups (Table 11). Due to this variation, we analyzed IgM
status in relation to clinical and histological features of melanoma. In melanoma patients anti-
GD1a IgG type were positive in 0,78% cases and IgM in 14,06% cases.
Gangliosides and Antigangliosides in Malignant Melanoma
http://dx.doi.org/10.5772/59176
377
Groups Antibodies type Positive Negative P
Melanoma
IgG 1 127 NS
IgM 18 110 <0.05
Dysplastic nevi
IgG 0 48 NS
IgM 3 45 NS
Control
IgG 0 48 1
IgM 0 48 1
p-melanoma vs control, dysplastic vs control, NS=no statistical significance
Table 11. Anti-GD1a IgG and IgM class in patients with malignant melanoma, dysplastic nevi and control
Anti-GD1a IgM status was analyzed in relation to age, sex, histological characteristics of
the tumor (Breslow index, Clark level, histological type of the tumor, presence/absence of
ulceration) (Table 12). The intensity level did not vary with sex and age or histological type
of  melanoma.  The  antibodies  varied  with  tumor  site:  the  highest  intensity  was  deter‐
mined in melanoma situated on trunk (p<0.05), followed by melanomas on head and neck
(p<0.05) compared with melanomas on limbs. High intensity of anti-GD1a were observed
in  melanoma  with  Breslow  2.01-3.0mm  (p<0.05),  respectively  Breslow>3.01mm  (p<0.05)
compared with Breslow 0.0-1.0mm. Increased intensity of anti-GD1a were determined in
Clark IV (p<0.05), respectively Clark V (p<0.05) compared with Clark II melanomas. Anti-
GD1a signal intensity varied significantly with ulceration, with higher levels in ulcerated
melanomas (p<0.05) (Table 12).
Parameters IgM signal intensity p
Sex
Women 12.96±24.08 p1=0.93Men 13.32±23.34
Tumor site
Head-neck 10.42±8.31
p2=0.03Trunk 16.26±6.65
Limbs 2.38±83.22
Histological type
Nodular melanoma 25.25±30.38
p3=0.70
Extensive in surface melanoma 2.37±1.76
Lenticular melanoma 2.54±1.76
Acral lenticular melanoma 2.33±1.38
Breslow index
0,0-1.0 mm 2.45±1.71
p4=0.031.01-2.0 mm 2.41±1.74
2.01 – 3.0mm 8.93±5.48
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Parameters IgM signal intensity p
> 3.01 mm 25.01±35.92
Clark level
II 2.40±1.71
p5=0.01
III 4.57±10.34
IV 19.55±26.08
V 38.66±36.54
Ulceration
Melanoma with ulceration 46.65±38.07 p6=0.00Melanoma without ulceration 8.33±16.16
p<0.05 was considered with statistically significance for IC=95%. p1-women vs men, p2-trunk vs limbs, p3-nodular mel‐
anoma vs extensive in surface melanoma, p4-Breslow<1.0mm vs Breslow>3.01mm, p5-Clark II vs Clark V, p6-ulcerated
melanoma vs melanoma without ulceration
Table 12. Anti-GD1a antibodies IgM class in relation to clinical and histological features of melanoma
3.2.5. Anti-GD1b prevalence in studied groups
In patients with malignant melanoma, signal of antiganglioside antibodies anti-GD1b IgG type
was undetectable in 61.71% patients, with low intensity in 34.37% patients, with medium
intensity in 3.12% patients. In dysplastic nevi group, signal of antiganglioside antibodies anti-
GD1b IgG type was undetectable in 81.25% cases, with low signal in 18.75% cases. In patients
with malignant melanoma, signal of antiganglioside antibodies anti-GD1b IgM type was
undetectable in 64.84% patients, with low intensity in 25.10% patients, with medium intensity
in 4.68% patients and high intensity in 5.46% patients (Table 13).
Groups Antibodies type Positive Negative p
Melanoma IgG 4 124 NSIgM 13 115 <0.05
Dysplastic nevi IgG 0 48 NSIgM 2 46 NS
Control IgG 0 48 1IgM 0 48 1
p-melanoma vs control, dysplastic vs control, NS=no statistical significance
Table 13. Anti-GD1b IgG and IgM class in patients with malignant melanoma, dysplastic nevi and control
In dysplastic nevi group, signal of anti-GD1b IgM type was undetectable in 81.25% cases, with
low signal in 5.46% cases, and with medium intensity in 1.56% cases. No positive anti-GD1b
IgM type were detected in nevi or control groups. In melanoma patients anti-GD1b IgG type
were positive in 3.12% cases, while IgM in 10.14% cases. Anti-GD1b IgG class had no significant
variations between groups, while, IgM class modified significantly (Table 13).
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Anti-GD1b IgM status was analyzed in relation to age, sex, histological characteristics of the
tumor (Breslow index, Clark level, histological type of the tumor, presence/absence of
ulceration) (Table 14). We did not determine significant variations of anti-GD1b except with
the histological type of melanoma. Compared with nodular melanoma, we detected statisti‐
cally increased intensity in extensive in surface melanoma (p<0.05) and acral lentiguos
melanoma (p<0.05).
Parameters IgM signal intensity P
Sex
Women 7.67±12.57 p1=0.52Men 9.36±16.02
Tumor site
Head-neck 10.57±21.36
p2=0.14Trunk 6.74±12.44
Limbs 14.30±20.88
Histological type
Nodular melanoma 6.00±11.40
p3=0.00
Extensive in surface melanoma 13.72±18.44
Lenticular melanoma 7.36±15.95
Acral lenticular melanoma 16.55±19.00
Breslow index
0-1.0 mm 13.72±18.49
p4=0.14
1.01-2.0 mm 11.52±18.17
2.01 – 3.0mm 6.43±14.07
>3.01 mm 5.65±8.33
Clark level
II 12.44±16.85
p5=0.35
III 9.29±15.93
IV 6.44±13.88
V 5.88±7.22
Ulceration
Melanom with ulceration 4.56±6.19 p6=0.23Melanom without ulceration 3.92±5.36
p<0.05 was considered with statistically significance for IC=95%. p1-women vs men, p2-trunk vs limbs, p3-nodular mel‐
anoma vs extensive in surface melanoma, p4-Breslow<1,0mm vs Breslow>3,01mm, p5-Clark II vs Clark V, p6-ulcerated
melanoma vs melanoma without ulceration
Table 14. Anti-GD1b antibodies IgM class in relation to clinical and histological features of melanoma
3.2.6. Anti-GT1b prevalence in studied groups
In patients with malignant melanoma, signal of anti-GT1b IgG type was undetectable in 83.59%
patients, with low intensity in 16.40% patients. In dysplastic nevi group, signal of anti-GT1b
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IgG type was undetectable in 85.41% cases, with low signal in 14.58% cases. In patients with
malignant melanoma, signal of anti-GT1b IgM type was undetectable in 53.24% patients, with
low intensity in 33.59% patients, with medium intensity in 10.93% patients and high intensity
in 3.12% patients. In dysplastic nevi group, signal of anti-GT1b IgM type was undetectable in
68.75% cases, with low signal in 27.08% cases, and with medium intensity in 4.16% cases. No
positive anti-GT1b IgM or IgG type were detected in control group. The statistical analysis
showed that IgM antibodies varied significantly between the studied groups (Table 15). We
analyzed IgM status in relation to clinical and histological features of melanoma.
Groups Antibodies type Positive Negative p
Melanoma
IgG 0 128 NS
IgM 18 110 <0.05
Dysplastic nevi
IgG 0 48 NS
IgM 2 46 NS
Control
IgG 0 48 1
IgM 0 48 1
p-melanoma vs control, dysplastic vs control, NS=no statistical significance
Table 15. Anti-GT1b IgG and IgM class in patients with malignant melanoma, dysplastic nevi and control
Anti-GT1b status was analyzed in relation to age, sex, histological characteristics of the tumor
(Breslow index, Clark level, histological type of the tumor, presence/absence of ulceration)
(Table 16). We did not determine significant variations of anti-GD1b except with the tumor
site of melanoma. Compared with melanomas on head-neck, we detected statistically in‐
creased intensity in melanomas on trunk (p<0.05) or on limbs (p<0.05).
Parameters IgM signal intensity p
Sex
Women 8.59±13.30
p1=0.53
Men 9.23±14.97
Tumor site
Head-neck 2.85±2.79
p2=0.02Trunk 7.36±13.46
Limbs 16.15±19.12
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Histological type
Nodular melanoma 6.61±14.96
p3=0.10
Extensive in surface melanoma 13.27±17.92
Lenticular melanoma 6.31±4.84
Acral lenticular melanoma 16.33±16.62
Breslow index
0-1.0 mm 13.27±17.92
p4=0.07
1.01-2.0 mm 11.47±11.04
2.01 – 3.0mm 2.75±2.04
>3.01 mm 7.85±16.35
Clark level
II 12.18±16.28
p5=0.28
III 9.74±10.76
IV 5.33±13.25
V 9.44±19.85
Ulceration
Melanom with ulceration 2.75±1.69
p6=0.23Melanom without ulceration 9.86±15.03
p<0.05 was considered with statistically significance for IC=95%. p1-women vs men, p2-trunk vs limbs, p3-nodular mel‐
anoma vs extensive in surface melanoma, p4-Breslow<1.0mm vs Breslow>3.01mm, p5-Clark II vs Clark V, p6-ulcerated
melanoma vs melanoma without ulceration
Table 16. Anti-GT1b antibodies IgM class in relation to clinical and histological features of melanoma
3.2.7. Anti-GQ1b prevalence in studied groups
In all patients with malignant melanoma, dysplastic nevi and control group, antiganglioside
antibodies anti-GQ1b IgG type were negative. In patients with malignant melanoma, signal of
antiganglioside antibodies anti-GQ1b IgM type was undetectable in 90.62% patients, with low
intensity in 4.68% patients, with medium intensity in 3.90% patients and high intensity in 0.78%
patients. No positive anti-GT1b IgM type were detected in dysplastic nevi, respectively, control
groups. No statistical differences were observed in anti-GQ1b IgG class status between
melanoma, dysplastic nevi and control group. Anti-GQ1b IgM class varied significantly
between the studied groups (Table 17). We analyzed IgM status by clinical and histological
features of melanoma.
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Groups Antibodies type Positive Negative p
Melanoma
IgG 0 128 NS
IgM 6 122 <0,05
Dysplastic nevi
IgG 0 48 NS
IgM 0 48 NS
Control
IgG 0 48 1
IgM 0 48 1
p-melanoma vs control, dysplastic vs control, NS=no statistical significance
Table 17. Anti-GQ1b IgG and IgM class in patients with malignant melanoma, dysplastic nevi and control
Anti-GQ1b IgM status was analyzed in relation to age, sex, histological characteristics of the
tumor (Breslow index, Clark level, histological type of the tumor, presence/absence of
ulceration) (Table 18) The intensity level did not vary with sex and age, tumor site or histo‐
logical type of melanoma, Clark level, Breslow index, presence/absence of ulceration.
Parameters IgM signal intensity p
Sex
Women 4.69±8.91
p1=0.32
Men 4.84±10.27
Tumor site
Head-neck 2.00±1.52
p2=0.30Trunck 4.60±7.61
Limbs 6.69±16.76
Histological type
Nodular melanoma 3.45±5.94
p3=0.16
Extensive in surface melanoma 6.81±17.13
Lenticular melanoma 5.90±9.64
Acral lenticular melanoma 9.77±12.22
Breslow index
0-1.0 mm 6.81±17.13 p4=0.70
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1.01-2.0 mm 4.44±7.03
2.01 – 3.0mm 2.81±1.72
>3.01 mm 5.03±8.92
Clark level
II 5.66±15.60
p5=0.60
III 5.68±8.64
IV 2.97±1.62
V 4.72±10.68
Ulceration
Melanoma with ulceration 2.87±1.78
p6=0.82Melanoma without ulceration 5.05±10.33
p<0.05 was considered with statistically significance for IC=95%. p1-women vs men, p2-trunk vs limbs, p3-nodular mel‐
anoma vs extensive in surface melanoma, p4-Breslow<1.0mm vs Breslow>3.01mm, p5-Clark II vs Clark V, p6-ulcerated
melanoma vs melanoma without ulceration
Table 18. Anti-GQ1b antibodies IgM class in relation to clinical and histological features of melanoma
3.3. The relationship between gangliosidic system and biochemical factors used for
melanoma staging
In this section we will  present the statistical correlations between LDH, CRP and IL8 in
melanoma patients, before the surgical removal of the tumor, and also, the relation between
the  biochemical  factors  and  serum  gangliosides/antigangliosides  in  melanoma  patients
(Table 19).
LDH CRP IL8
IL8 r=0.36p=0.00
r=0.92
p=0.00 -
CRP r=0.40p=0.00 - -
Serum
gangliosides (LASA)
r=0.44
p=0.00
r=0.43
p=0.00
r=0.47
p=0.00
Table 19. The correlations between gangliosidic system and staging factors in malignant melanoma patients
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In melanoma group positive statistical significant correlations were determined between LDH
and Il8, LDH and CRP, respectively, CRP and IL8. A strong positive correlation was detected
between serum gangliosides and LDH, CRP and IL8 in melanoma group.
LDH CRP IL8
Anti-GM1 r=0.75p=0.00
r=0.33
p=0.00
r=0.37
p=0.00
Anti-GM2 r=0.07p=0.38
r= - 0.06
p=0.47
r= - 0.03
p=0.67
Anti-GM3 r= - 0.12p=0.16
r= - 0.17
p=0.05
r= - 0.15
p=0.02
Anti-GD1a r=0.140p=0.00
r=0.45
p=0.00
r=0.53
p=0.00
Anti-GD1b r= - 0.15p=0.06
r= - 0.24
p=0.00
r= - 0.22
p=0.00
Anti-GT1b r= - 0.16p=0.05
r= - 0.29
p=0.00
r= - 0.25
p=0.00
Anti-GQ1b r= - 0.02p=0.81
r= - 0.13
p=0.11
r= - 0.15
p=0.09
Table 20. The correlations between antigangliosides and staging factors in malignant melanoma patients
Anti-GM1 correlated positive, statistically significant with LDH, CRP and IL8. Anti-GM2 IgM
type correlated weakly, statistically insignificant with the markers used for melanoma staging.
Anti-GM3 was negatively associated before surgical intervention, with the markers that
indicate the progression of melanoma: statistically insignificant with LDH, statistically
significant with CRP respectively, IL8. Anti-GD1a was strongly positive associated with the
markers for melanoma staging, before surgical intervention. The b serie of antiganglioside
antibodies correlated weakly, negatively, with LDH, CRP and IL8.
3.4. Variation of gangliosidic system in melanoma patients after surgical intervention
From the 128 patients with malignant melanoma, we selected 30 cases with the same clinical
stage (I or II), that were monitored for 36 months using the same investigation protocol. The
decision to continue monitoring without receiving any treatment was based on oncologist
decision, no signs of melanoma evolution, and also on patients attitude/agreement. The
moments of evaluation were: T0-when included in the study; T1 – 8 weeks after surgical
removal of the tumor, at 3(T2), 6 (T3), 12 (T4), 18 (T5) and 36 (T6) months after surgical removal
of the tumor (Table 21).
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T1 T2 T3 T4 T5 T6
LASA 40.73±28.40 41.86±28.49 42.30±30.55 44.60±32.22 45.53±34.54 53.11±41.26(1)
Anti-GM1 8.14±12.16 7.80±11.40 6.22±7.12 8.15±9.30 9.33±7.24 13.10±10.25(1)
Anti-GM2 14.35±7.85 10.26±8.20 12.15±5.12 9.37±8.75 10.6±6.25 5.22±6.10
Anti-GM3 10.66±12.37 6,15±10.27(1) 4.06±3.86(1) 6.04±9.05(1) 4.60±8.15(1) 3.90±5.10(1)
Anti-GD1a 17.42±18.32 14,05±9.61 20.10±16.10 21.17±9.25 18.00±10.82 23.10±11.50(1)
Anti-GD1b 11.15±9,10 17.10±6.33 15.16±5.15 11,10±8.32 9.11±8.17 8.30±6.25
Anti-GT1b 11.15±18.10 16.22±17.02 10.61±8.33 8.62±6.55 7.14±8.09(1) 8.32±10.12
Anti-GQ1b 4.10±6,44 6.22±5.17 8.77±10.21(1) 9.40±7.25(1) 6.18±7.35 10.40±7.35
1)=statistically significant variation compared with moment 1
Table 21. Variation of serum gangliosides and antiganglioside antibodies after surgical removal of melanoma
LASA increased after surgical intervention, having the biggest level at T6, its variation being
statistically significant (p<0.05). Anti-GM1 decreased in the first six months after surgical
removal of melanoma, afterwards its level increased, at T6 being statistically significant higher
compared with its level at T1 (p<0.05). Anti-GM2 decreased during the 36 months of evalua‐
tion, but its variation was not statistically significant (p>0.05). Anti-GM3 decreased signifi‐
cantly at T2, T3, T4, T5, and respectively, at T6 compared with T1. Anti-GD1a increased
significantly during the 36 months of evaluation compared with its level at T1. Antigangioside
antibodies from b series had a sinuous variation during evaluation: anti-GD1b increased in
the first 12 months after surgical removal of the tumor, afterwards, its intensity decreased
compared with T1; anti-GT1b increased at T2, and then, its intensity decreased during
evaluation; anti-GQ1b increased during evaluation.
After surgical removal of melanoma we detected anti-GM3 IgM type in 12 patients, data that
could indicate the regression of melanoma. High pathological levels of serum gangliosides
and detectable levels of anti-GD1a IgM were determined in 11 patients, data that could be
associated with progression of melanoma and possible metastasis. The increase of serum
gangliosides, during evaluation and the absence of antiganglioside antibodies in 7 patients
suggest tumoral recurrence.
3.5. Determination of relapse-free survival in malignant melanoma patients
We determined the relapse free survival using Kaplan-Meier curves, in patients with operated
malignant melanoma, monitored for 36 months. Survival rate was assessed in relation to serum
levels of gangliosides, anti-GM3 IgM type and anti-GD1a IgM type. We choose a cut-off value
suitable for estimating the prognosis.
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Biological parameters Free-relapse survival (months) p
Serum gangliosides (mg/dl) ≤25 22.15±1.19 1
>25 16.33±1.72 0.01
Anti-GM3/IgM ≤14.20 17.82±0.94 1
>14.20 21.32±1.53 0.04
Anti-GD1a/IgM ≤15.35 21.67±1.04 1
>15.35 13.85±1.37 0.00
p –statistical significance
Table 22. Free-relapse survival in patients with malignant melanoma
The relapse-free survival curves in relation to serum gangliosides showed an increase in
survival in patients with serum gangliosides lower than 25mg/dl compared with those that
had gangliosides over 25mg/dl (22.15±1.19 versus 16.33±1.72 months, p<0.05) (Table 22). The
relapse-free survival curves in relation to serum anti-GM3 IgM type showed an increase in
survival in patients with signal intensity over 14,20 compared with patients with lower anti-
GM3 intensity signal (21.31±1.53 versus 17.82±0.94 months, p<0.05) (Table 22). The relapse-free
survival curves in relation to serum anti-GD1a IgM type showed an increase in survival in
patients with signal intensity under 15.35 compared with patients with higher anti-GM3
intensity signal (13.85±1.37 versus 21.67±1.04 months, p<0.05) (Table 22).
4. Discussions
There is little information about quantitative variations of serum gangliosides, their origin and
progression of malignant melanoma in medical literature. Serum gangliosides are derived on
one hand, from tumor microenvironment, and, on the other hand, from membranous compo‐
nents turn-over. The ability of melanoma cells to synthetize and release gangliosides in
extracellular space are sustained by the results of this study.
Though, in systemic circulation, we detected high levels of gangliosides in patients with
primary melanoma and metastatic melanoma compared with dysplastic nevi and control
groups. The patients with metastatic melanoma had significantly increased levels of ganglio‐
sides compared with patients with primary tumor. The serum levels of gangliosides were
similar in nevi and control group.
Important data regarding the origin of serum gangliosides were obtained by analyzing their
levels before and after surgical removal of melanocytic tumors. The levels of serum ganglio‐
sides varied statistically significant with surgical intervention in patients with localized
melanoma, and without statistical significance in patients with metastatic melanoma, respec‐
tively, dysplastic nevi. Therefore, serum concentration of gangliosides could give important
data about tumor mass, tumor volume or tumor progression. We consider that low levels of
Gangliosides and Antigangliosides in Malignant Melanoma
http://dx.doi.org/10.5772/59176
387
gangliosides in multiple determinations after surgical removal of the tumor could indicate a
correct surgical treatment of melanoma, while high levels in the same conditions could mean
a progression of melanoma.
Our study showed a strong association between increased serum gangliosides and high
Breslow index or high Clark level and presence of ulceration. Serum gangliosides correlat‐
ed strong and positive with biological factors used for melanoma staging – LDH, CRP, IL8.
High levels of LDH, CRP, IL8 are markers for melanoma progression. These correlations
show that the principle elements involved in melanoma progression are vascularization and
neoangiogenesis.
Therefore, the levels of serum gangliosides could become a useful marker for clinical staging
of melanoma, but its usage is limited by the lack of satisfactory criteria for interpretation. The
problem becomes more complex, because there are multiple sources of serum gangloside,
being difficult to know if the exact source are the tumoral cells or the host organism. This
statement is sustained by the variability in composition of serum gangliosides and altered
immunologic reactivity of melanoma patients. In the model of serum gangliosides before and
after surgical treatment, we observed a tendency of the body to adjust the biosynthesis of
gangliosides, mainly by normalizing glycosyltransferase activity in melanoma patients. To
demonstrate a possible link between ganglioside system and prognosis of patients with
cutaneous malignant melanoma, we calculated relapse-free survival of the disease according
to serum levels of gangliosides. Based on this analysis, the authors found that low levels of
circulating gangliosides are positive prognosis factors, in terms of increasing the relapse free
survival in patients with malignant melanoma. These results justify the role of serum gan‐
gliosides as potential biomarkers in the management of patients with melanoma, a finding that
supports previous researches [10, 11, 53, 102, 103].
Data in literature about the involvement of gangliosides in tumor processes are controversial.
Some studies claim that overexpression of gangliosides on cells membrane and their accumu‐
lation in intercellular space and in serum of patients with cancer may play a role in tumor
growth, neovascularization, and lack of immune response. Gangliosides influence tumor
metastasis and angiogenesis by modulating the autocrine production of growth factors and
thereby, protect the tumor from the host's immune system [67, 98, 100, 101,104, 105, 106].
In this sense, the relationship between ganglioside, tumor growth and progression have been
the subject of several studies. A number of in vivo and in vitro studies have shown that
gangliosides are involved in tumor suppression. Gangliosides metabolic products such as
ceramides may be involved in apoptosis. Other studies argue that metastatic melanoma
produces a variety of growth factors and interleukins that induce cell proliferation. Ganglio‐
sides can alter the growth of metastatic melanoma by modulation the activity of some growth
factors, by regulating cAMP and some signaling pathways. Recently it has been demonstrated
that gangliosides of human melanoma promote differentiation of dendritic cells from mono‐
cytes, maturation of Langerhans cells in the epidermis, and induce apoptosis of both cell types.
Melanoma cells release active chemo attractants and other mediators to stimulate the migration
and activation of macrophages, monocytes, granulocytes, keratinocytes, fibroblasts, platelets,
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and other components of the native immunity. Metastatic melanoma release these molecules
in the tumor microenvironment [52, 82, 99, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117].
Other studies claim that metastatic melanoma produces a number of growth factors such as
interleukin-8, alpha protein that regulates the growth/the activity of melanocytes. It has been
suggested that gangliosides could alter the growth of metastatic melanoma by modulating the
production of an autocrine growth factor and by adjusting the 3 '5'adenozin cyclic monophos‐
phate (cAMP) and its corresponding signaling paths. Other studies have suggested that soluble
gangliosides could be involved in tumor-induced immunosuppression [98, 111, 112, 115, 116,
117, 118, 119].
Melanoma cells, especially those of metastatic melanoma overexpress a variety of ganglio‐
sides. Aberrant gangliosides and their high level could be a marker of malignancy. Serum
levels of compounds with sialic acid did not vary in patients with precancerous pigmenta‐
ry lesions. We observed that in early diagnosed melanoma serum level of gangliosides was
not  significantly  increased.  Low  levels  of  gangliosides  in  melanoma  patients  without
ulceration  or  metastasis  were  associated  with  an  increased  relapse-free  survival  after
surgical  removal  of  the  tumor.  High  levels  of  gangliosides  in  patients  with  metastatic
melanoma were associated with progression of the disease and a decrease in relapse-free
survival after surgical intervention [49, 53, 103].
The presence in the body of glicosphingolipids antigens, recognized by the immune system
as nonself, determines the proliferation of some lymphocitary clones, that promote the
synthesis of antibodies against these molecules. Glicosphigolipids associated with tumors,
induce also, the synthesis of antibodies against gangliosides by a complex mechanism. It was
accepted the idea of genetic similarity between some exogenous antigens and some compo‐
nents of nervous cells.
The umoral immune response in adult patients with untreated malignant melanoma, in
dysplastic nevi and healthy volunteers was evaluated by the assessment of antigangliosides
of IgG and IgM type against GM1, GM2, GM3, GD1a, GD1b, GT1b, GQ1b. In healthy individ‐
uals, antigangliosides antibodies IgG and IgM type were negative, in dysplastic nevi group,
antibodies IgG type were absent, with the exception of anti-GM1 that were present in 4.17%
cases. Antibodies IgM type had the following distribution: 6.25% anti-GM1; 4.17% anti-GM2;
4.17% anti-GM3; 6.25% anti-GD1a; 4.17% anti-GD1b; 4.17% anti-GT1b; 0% anti-GQ1b. In
melanoma group, IgG antibodies had the following distribution: 4.68% anti-GM1; 1.56% anti-
GM2; 0.78% anti-GM3; 0.78% anti-GD1a; 3.12% anti-GD1b, while the positive IgM were 15.63%
anti-GM1; 20.31% anti-GM2; 17.19% anti-GM3; 14.06% anti-GD1a; 10,16% anti-GD1b; 14.06%
anti-GT1b; 4.69% anti-GQ1b. No statistical differences were observed in IgG status between
the studied groups. Significant variations of IgM antibodies were determined between
melanoma and nevi, respectively control group.
Based on these results, we can appreciate that gangliosides expressed on melanoma cells
induced the synthesis of antiganglioside antibodies. The presence of antiganglioside antibod‐
ies was associated with oncogenic transformation of melanocytes, but the moment of anti‐
bodies synthesis could not be determined. The antibodies identified in melanoma patients
were mostly of IgM type.
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To evaluate if the presence of IgM antibodies was associated with melanoma development,
we determined their relation to clinical, histological and biological factors recommended by
AJCC for melanoma staging. Anti-GM1 varied significantly with tumor site, histological site
of melanoma, Breslow index, Clark level, presence of ulceration, anti-GM2 did not vary with
histological characteristics of melanoma, anti-GM3 varied significantly with Clark level and
presence of ulceration and anti-GD1a was influnced significanlty by tumor site, Breslow index,
Clark level and presence of ulceration. Anti-GD1b was influenced significantly by histological
type of melanoma, anti-GT1b only by tumor site, while anti-GQ1b was not influenced by
histological characteristics of melanoma.
Positive correlation with statistical significance were determined between anti-GM1 and LDH,
CRP, respectively, IL8, between anti-GD1a and LDH, CRP, respectively, IL8. Negative
significant correlations were observed between anti-GM3, anti-GT1b and LDH, CRP, respec‐
tively, IL8. The transition from radial to vertical growth of melanoma marked by high levels
of LDH, CRP and IL8 was associated with an increase in anti-GM1, anti-GD1a and a decrease
in anti-GM3, anti-GM2 antibodies of IgM type. Therefore, the IgM antibodies against GM1 and
GD1a might be useful in malignant melanoma staging and diagnosis. Also, they could facilitate
tumor growth by promoting neovascularization, inflammation and angiogenesis.
Other important findings of our study are the potential protective role of anti-GM2 and anti-
GM3 antibodies of IgM type in melanoma patients. Anti-GM2 and anti-GM3 could affect
gangliosides expression on melanoma cells, and though, might influence indirectly cell
proliferation, transmembrane signaling and cells interaction. IgM antibodies against GD1b,
GT1b, GQ1b offered no data about melanoma progression in relation to analyzed histological
factors. Their negative correlation with IL8, LDH and CRP suggest that they could suppress
tumor growth and angiogenesis indirectly.
Ganglioside and antiganglioside antibodies could be used for melanoma staging and though,
they could increase the precision of the outcome. High levels of gangliosides and anti-GM1
and GD1a before the surgical removal of the tumor were associated with advanced melanoma
and poor prognosis. The presence of anti-GM2,-GM3,-GD1b,-GT1b,-GQ1b in patients with
dysplastic nevi could be suggestive of malignant transformation. Assessment of gangliosides
and antigangliosides before the surgical intervention could be an important item for the post-
surgical follow-up.
Other studies in patients with prostate cancer or soft tissue sarcoma showed that anti-GM1
antibodies had no value for diagnose and prognosis. In patients with thyroid cancer well
differentiated, the level of anti-GM1 IgG and IgM type was associated with carcinogenesis,
with no diagnose value in thyroid cancer [120, 121, 122]. In a big cohort of patients with lupus
systemic erythematous the presence of both anti-GM1 IgM and IgG type were associated with
neuro-psychiatric disorders and depression. Anti-GM1 were identified in the serum of patients
with chronic idiopathic hepatitis, in systemic infections, autoimmune disorders with neuro‐
logical involvement (encephalopathy, HIV neuropathy) and after parenteral administration of
gangliosides [123, 124, 125, 126, 127, 128, 129, 130].
Manipulation of cellular growth dependent of GD1b, GT1b, GQ1b gangliosides was demon‐
strated in several cellular systems. In vitro growth of human metastatic melanoma WM266-4
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was inhibited by GD1b, GT1b, GQ1b, while other gangliosides (GM 1, GM2, GM3, GD1a, GD2
and GD3) had no effect. The action of gangliosides from b series was inhibited by IL8. This
phenomena could be antagonized by exogenous anti-IL8. No other growth factor (regulating
of oncogene alpha growth factor, platelet regulating growth factor, interleukin 6) influenced
melanoma evolution. A possible mechanism through which GD1b, GT1b and GQ1b inhibit
melanoma growth could be the suppression of IL8 secretion, of ARNm expression and
activation. Other studies suggest that GD1b could determine melanoma progression in vivo
by stimulating angiogenesis. GT1b also influenced growth and motility of endothelial cells,
while GM3 had an angiostatic effect. Multiple results proved the role of anti-GD1b,-GT1b,-
GQ1b IgM type in soft tissue sarcoma Erlich subcutaneous solid tumor, Erlich carcinoma with
ascitis [76, 121, 131, 132, 133, 134].
The ability of the human organism to promote an anti-GM1,-GM2,-GM3,-GD1a,-GD1b-GT1b,-
GQ1b immune response could influence the evolution of patients with malignant tumors.
Taking into account the immunogenic capacity of gangliosides in malignant melanoma and
their effect on tumor development, we consider that an action on gangliosides metabolism
could be a strategy of reducing tumor angiogenesis. Low gangliosides and increased antibod‐
ies against gangliosides from melanoma cells confer an advantage in survival of melanoma
patients compared with patients without antiganglioside antibodies. Based on our results
regarding gangliosides and antigangliosides profile in patients with cutaneous malignant
melanoma, the authors consider that pharmacological modulation of ganglioside-antiganglio‐
side system could be a way to control melanoma development.
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